Lifefirst Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.60 Cr
as on 29-10-2024
- Paid Up Capital ₹ 1.57 Cr
as on 29-10-2024
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 47.50 Cr
as on 29-10-2024
- Revenue 3468.49%
(FY 2023)
- Profit 49.89%
(FY 2023)
- Ebitda -26.11%
(FY 2023)
- Net Worth -0.21%
(FY 2023)
- Total Assets 111.88%
(FY 2023)
About Lifefirst Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.60 Cr and a paid-up capital of Rs 1.57 Cr.
The company currently has active open charges totaling ₹47.50 Cr.
Rajesh Mehta, Vivek Shrivastava, Rishabh Mehta, and One other member serve as directors at the Company.
- CIN/LLPIN
U24290MP2020PTC051311
- Company No.
051311
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 May 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lifefirst Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishabh Mehta  | Director | 04-May-2020 | Current |
| Vivek Shrivastava | Director | 10-Mar-2021 | Current |
| Rajesh Mehta | Director | 04-May-2020 | Current |
| Rohit Mehta | Director | 10-Mar-2021 | Current |
Financial Performance and Corporate Structure Insights of Lifefirst Pharma.
Lifefirst Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 3468.49% increase. The company also saw a substantial improvement in profitability, with a 49.89% increase in profit. The company's net worth dipped by a decrease of 0.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lifefirst Pharma?
Unlock access to Lifefirst Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Bcm Infrastructure Private LimitedActive 3 years 7 months
Rishabh Mehta and Rohit Mehta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Dec 2021 | ₹47.50 Cr | Open |
How Many Employees Work at Lifefirst Pharma?
Lifefirst Pharma has a workforce of 51 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lifefirst Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lifefirst Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
